Evaluating CTIM-76 for patients with recurring ovarian and other advanced cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 study aims to assess the safety and efficacy of CTIM-76, a bispecific antibody targeting CLDN6, in patients with platinum-resistant ovarian cancer and other advanced solid tumors such as testicular and endometrial cancers. The trial consists of a dose escalation phase to determine the recommended dose for expansion and a subsequent dose expansion phase to evaluate the drug's effectiveness at selected doses. Participants will receive CTIM-76 weekly for 28-day cycles until disease progression or unacceptable toxicity occurs. The study will also analyze dose-response relationships based on safety and efficacy data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants with CLDN6 positive platinum resistant/refractory ovarian, advanced testicular or advanced endometrial cancer.
* Participants with measurable disease per RECIST 1.1.
* ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks.
* Participants with adequate organ function.

Exclusion Criteria:

* Evidence of central nervous system metastases, leptomeningeal disease or spinal cord compression.
* Uncontrolled significant active infection or any medical or other condition that in opinion of the Investigator would preclude the participant's participation in the study.
* Concurrent participation in another investigational clinical trial.

Where it's running

• University of Arkansas Winthrop P. Rockefeller Cancer Institute
  Little Rock, Arkansas, United States Recruiting
• SCRI at Denver Health
  Denver, Colorado, United States Recruiting
• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting
• University of Nebraska Medical
  Omaha, Nebraska, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting
• Duke Cancer Institute
  Durham, North Carolina, United States Recruiting

Study contacts

• Study coordinator: Context Clinical Development
• Email: cntx-ctim76-101@contexttherapeutics.com
• Phone: 267-225-7416

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• OPB-201 therapy for recurrent endometrial and platinum-resistant ovarian cancer

  A one-time treatment with a patient’s own T cells engineered to target PRAME is being tested to see if it is safe and what dose works best for adults with recurrent endometrial cancer or platinum-resistant ovarian cancer.

  Recruiting at 5 sites Phase 1 Outpace Bio, Inc. · San Francisco, California and 4 other locations · NCT07664735

• MUC16-targeted antibody-drug HWK-016 for advanced ovarian and endometrial cancer

  This will test HWK-016, an antibody-drug that targets MUC16, in adults with advanced or metastatic ovarian or endometrial cancer, including platinum-resistant ovarian cancer.

  Recruiting at 9 sites Phase 1 Whitehawk Therapeutics, Inc. · Little Rock, Arkansas and 11 other locations · NCT07470853

• HWK-007, a PTK7-targeted antibody‑drug conjugate for advanced PTK7-positive ovarian, endometrial, and certain non‑squamous lung cancers

  This study will try HWK-007, a PTK7-targeted antibody‑drug conjugate given every three weeks, to see if it can shrink or control advanced PTK7-positive ovarian, endometrial, or non-squamous EGFR wild-type lung cancers.

  Recruiting at 10 sites Phase 1 Whitehawk Therapeutics, Inc. · Little Rock, Arkansas and 11 other locations · NCT07444814

• Navigation program for young cancer survivors

  This project tests an adapted navigation program to help adolescent and young adult cancer survivors get timely care within Kaiser Permanente Southern California.

  Recruiting Kaiser Permanente · Pasadena, California · NCT07406087

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Testing GV20-0251 for advanced or treatment‑resistant solid tumors

  This study will test whether GV20-0251 is safe and tolerable when given every three weeks to adults with advanced or treatment‑resistant solid tumors such as liver, lung, pancreatic cancer, and melanoma.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07106827

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.